SION_OUT_1 [2025-04-02 12:39:08 -0400] 2214 Bytes | 614 tokens | Cum: 614 tkns (7.67% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 12:39:06 PM on Wed Apr 02, 2025 -0400, and I'm firing up the spotlight on Sionna Therapeutics (SION), moving from 10.16 to 11.88. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Sionna Therapeutics (SION)
IPO: IPO date unknown
Shares Outstanding: 44,120,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Sionna Therapeutics:

C1 - Mar-20-25 07:00AM - Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
C2 - Mar-15-25 04:43PM - Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month
C3 - Mar-06-25 10:25AM - Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently?
C4 - Mar-03-25 12:57PM - Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently
C5 - Feb-25-25 05:56AM - Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market
C6 - Feb-24-25 08:00AM - Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
C7 - Feb-17-25 04:43PM - Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year?
C8 - Feb-10-25 04:03PM - Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Sionna Therapeutics (SION)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SION_OUT_3 [2025-04-02 12:39:14 -0400] 1098 Bytes | 312 tokens | Cum: 928 tkns (11.60% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results**
Date: Mar-20-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046084/0/en/Sionna-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html

March 20, 2025 07:00 ET| Source:Sionna Therapeutics, Inc.Sionna Therapeutics, Inc.

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025

On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipated in mid-2026

Comp

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SION_OUT_5 [2025-04-02 12:39:15 -0400] 926 Bytes | 296 tokens | Cum: 1367 tkns (17.09% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T18:45:56Z - Sionna Therapeutics (NASDAQ:SION) Trading 4.5% Higher - Still a Buy?...
A2 - 2025-03-25T19:38:57Z - Sionna Therapeutics (NASDAQ:SION) Shares Down 4.2% - What's Next?...
A3 - 2025-03-22T15:43:02Z - Sionna Therapeutics (NASDAQ:SION) Reaches New 12-Month Low Following Weak Earnings...
A4 - 2025-03-21T16:15:44Z - Sionna Therapeutics (NASDAQ:SION) Shares Gap Up - Should You Buy?...
A5 - 2025-03-21T12:44:49Z - Sionna Therapeutics (NASDAQ:SION) Posts Quarterly Earnings Results, Misses Expectations By $0.70 EP...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SION_OUT_7 [2025-04-02 12:39:16 -0400] 1098 Bytes | 326 tokens | Cum: 1695 tkns (21.19% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Sionna Therapeutics (NASDAQ:SION) Trading 4.5% Higher - Still a Buy?**Date: 2025-03-26Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/sionna-therapeutics-nasdaqsion-trading-45-higher-still-a-buy-2025-03-25/Shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) were up 4.5% during mid-day trading on Tuesday . The company traded as high as $12.91 and last traded at $12.65. Approximately 11,004 shares traded hands during trading, a decline of 95% from the average daily volume of 231,585 shares. The stock had previously closed at $12.10.

A number of research firms have recently commented on SION. TD Cowen initiated coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating on the stock. Guggenheim assumed coverage on Sionna Therapeutics in a report on Tu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SION_OUT_9 [2025-04-02 12:39:17 -0400] 461 Bytes | 117 tokens | Cum: 1814 tkns (22.68% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-10T21:03:17Z - Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SION_OUT_11 [2025-04-02 12:39:20 -0400] 838 Bytes | 219 tokens | Cum: 2035 tkns (25.44% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/02/g43607841/sionna-therapeutics-announces-closing-of-219-2-million-upsized-initial-public-offering-including-fSionna Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising $219.2 million. The company is developing novel medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SION_OUT_13 [2025-04-02 12:39:21 -0400] 786 Bytes | 198 tokens | Cum: 2300 tkns (28.75% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-20 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and related notes a...

S3 - 2025-03-20 8-K Item2.02 Results of Oper and Fin Cond.

On March 20, 2025, Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the fiscal year ended December 31, 2024. The full text of the press release is furnished as E...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SION_OUT_15 [2025-04-02 12:39:22 -0400] 1098 Bytes | 222 tokens | Cum: 2524 tkns (31.55% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and related notes and other financial information included elsewhere in this Annual Report. This discussion and analysis and other parts of this Annual Report contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Risk Factors and elsewhere in this Annual Report. You should car

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SION_OUT_17 [2025-04-02 12:39:28 -0400] 1098 Bytes | 242 tokens | Cum: 2768 tkns (34.60% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): efully read the Risk Factors section of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Also see the section titled Cautionary Note Regarding Forward-Looking Statements.

Overview

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTRs nucleotide-binding domain 1 (NBD1). We believe stabilizing NBD1 is central to unlocking dramatic

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SION_OUT_19 [2025-04-02 12:39:39 -0400] 5585 Bytes | 1550 tokens | Cum: 4449 tkns (55.61% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 78,776 | Perf Month: -17.53% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 276.89K | Perf Quarter: - | Short Float: 6.43% | ROE: - |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.60 | Index: - | Short Ratio: 6.28 | ROI: - |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 36.05 | Market Cap: 538.58M | Short Interest: 1.74M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.73 | Shs Outstand: 44.12M | Beta: - | EPS Surprise: -164.75% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: -11.67% | Shs Float: 27.05M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -24.03% | Inst Own: 30.36% | Sales past 5Y: 0.00% | Earnings: Mar 20 BMO |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -24.03% | Insider Own: 38.70% | Employees: 41 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: 1.38% | Insider Trans: 25.50% | Debt/Eq: 0.06 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

Inside Trans: Sionna Therapeutics, Inc. (SION) by TPG GP A, LLC (Unknown Title) on 2025-02-10
- Common Stock: 4875547 shares at $N/A (I)
- Common Stock: 1125000 shares at $18 (I) Footnote: On February 10, 2025, in connection with the Issuer's initial public offering, The Rise Fund Sling, L.P. acquired an aggregate of 1,125,000 shares of Common Stock at a price of $18.00 per share.
- Series Seed Preferred Stock: 1276276 shares at $N/A (I)
- Series A Preferred Stock: 1806318 shares at $N/A (I)
- Series B Preferred Stock: 2275528 shares at $N/A (I)
- Series C Preferred Stock: 1765541 shares at $N/A (I)

Inside Trans: Sionna Therapeutics, Inc. (SION) by ORBIMED ADVISORS LLC (Unknown Title) on 2025-02-10
- Common Stock: 3154959 shares at $N/A (I)
- Common Stock: 550000 shares at $18 (I)
- Series B convertible preferred stock: 2560951 shares at $0 (I)
- Series C convertible preferred stock: 2048760 shares at $0 (I)

Inside Trans: Sionna Therapeutics, Inc. (SION) by Booth Bruce (Unknown Title) on 2025-02-10
- Common Stock: 2886293 shares at $N/A (I)
- Common Stock: 747727 shares at $N/A (I)
- Common Stock: 60000 shares at $18 (I)
- Series Seed convertible preferred stock: 1051051 shares at $0 (I)
- Series A convertible preferred stock: 1806317 shares at $0 (I)
- Series B convertible preferred stock: 1298332 shares at $0 (I)
- Series C convertible preferred stock: 61463 shares at $0 (I)
- Series C convertible preferred stock: 1092504 shares at $0 (I)

Inside Trans: Sionna Therapeutics, Inc. (SION) by Thompson Peter A. (Unknown Title) on 2025-02-10
- Common Stock: 3154959 shares at $N/A (I)
- Common Stock: 550000 shares at $18 (I)
- Series B convertible preferred stock: 2560951 shares at $0 (I)
- Series C convertible preferred stock: 2048760 shares at $0 (I)

Inside Trans: Sionna Therapeutics, Inc. (SION) by Ridloff Elena (CFO & Head of Corp. Dev.) on 2025-02-06
- Stock Option (Right to Buy): 157820 shares at $0 (D)

Inside Trans: Sionna Therapeutics, Inc. (SION) by Cloonan Michael (President & CEO) on 2025-02-06
- Stock Option (Right to Buy): 450252 shares at $0 (D)

Inside Trans: Sionna Therapeutics, Inc. (SION) by Viney Joanne L. (Unknown Title) on 2025-02-06
- Stock Option (Right to Buy): 39919 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 12.115
Average Volume: 234257.3
30-Day High: 17.11
30-Day Low: 10.16
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SION_OUT_21 [2025-04-02 12:39:41 -0400] 676 Bytes | 167 tokens | Cum: 4842 tkns (60.52% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SION_IN_23 [2025-04-02 12:39:41 -0400] 126 Bytes | 29 tokens | Cum: 4898 tkns (61.22% of 8k)
==========================================================================

====================================
[2025-04-02 12:39:41] # Analysis Completed
Elapsed Time: 34.87 seconds